KURA Kura Oncology, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1422143 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-35.0%
TTM EPS YoY-33.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-394.3%
Net margin-369.3%
FCF margin-112.4%
EBITDA margin-392.5%
Returns
ROE-224.9%
ROA-48.2%
ROIC (approx.)-389.8%
Asset turnover0.13x
Leverage & solvency
Liabilities / assets96.8%
Debt / equity0.55x
Current ratio3.60x
Interest coverage-227.12x
Cash quality & payout
Operating cash flow / net income0.29x
Accruals ratio-34.1%
Payout ratio—
Capex / revenue4.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $22.84M | $20.87M | $18.27M | $17.34M | $20.75M | $15.29M | $14.11M | — |
| Cost of revenue | $371,000 | $243,000 | $262,000 | — | — | — | — | — |
| Gross profit | $22.47M | $20.63M | $18.00M | — | — | — | — | — |
| R&D expense | $66.88M | $61.89M | $65.26M | $64.41M | $67.91M | $62.78M | $55.97M | $52.27M |
| SG&A expense | $30.25M | $31.75M | $31.55M | $39.14M | $32.84M | $25.17M | $22.84M | $24.07M |
| Operating income | -$74.66M | -$73.01M | -$78.81M | -$86.27M | -$80.00M | -$72.67M | -$64.70M | -$22.45M |
| Interest expense | $350,000 | $345,000 | $336,000 | $346,000 | $393,000 | $391,000 | $382,000 | $403,000 |
| Pretax income | -$70.22M | -$68.32M | -$73.33M | -$80.93M | -$74.12M | -$66.12M | -$57.20M | -$17.20M |
| Income tax | $0 | $5,000 | $8,000 | $71,000 | $0 | $0 | $226,000 | — |
| Net income | -$70.22M | -$68.33M | -$73.33M | -$81.00M | -$74.12M | -$66.12M | -$57.43M | -$19.22M |
| EBITDA | -$74.33M | -$72.64M | -$78.46M | -$85.86M | -$79.83M | -$72.44M | -$64.46M | -$22.25M |
| EPS (basic) | -0.78 | -0.77 | -0.83 | — | -0.85 | -0.75 | -0.66 | — |
| EPS (diluted) | -0.78 | -0.77 | -0.83 | — | -0.85 | -0.75 | -0.66 | — |
| Weighted avg. shares (diluted) | 89.82M | 88.86M | 88.61M | — | 87.64M | 87.59M | 87.42M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $57.94M | $70.24M | $39.08M | $149.10M | $95.29M | $81.95M | $51.27M | $224.46M |
| Short-term investments | $434.16M | $448.78M | $541.74M | $518.14M | $454.38M | $548.78M | $606.92M | $502.93M |
| Receivables | $14.48M | $9.45M | $9.35M | $8.80M | $35.94M | $4.57M | $48.75M | $2.06M |
| Inventory | $4.98M | $2.48M | $843,000 | $413,000 | — | — | — | $0 |
| Current assets | $534.70M | $559.44M | $623.78M | $708.66M | $620.66M | $660.08M | $724.20M | $744.83M |
| PP&E, net | $7.46M | $7.59M | $7.61M | $7.86M | $7.40M | $3.91M | $2.35M | $1.68M |
| Total assets | $566.50M | $587.79M | $652.55M | $738.36M | $649.38M | $682.42M | $743.76M | $760.16M |
| Current liabilities | $148.73M | $118.19M | $101.50M | $116.97M | $121.30M | $107.17M | $89.77M | $78.71M |
| Short-term debt | $8.53M | $4.22M | — | $0 | $4.34M | $3.11M | $1.92M | $2.61M |
| Long-term debt | $1.30M | $5.57M | $9.75M | $9.71M | $5.34M | $6.51M | $7.65M | $6.92M |
| Total debt | $9.83M | $9.79M | $9.75M | $9.71M | $9.67M | $9.62M | $9.57M | $9.52M |
| Total liabilities | $548.54M | $539.36M | $544.67M | $564.23M | $406.84M | $376.94M | $379.36M | $346.52M |
| Shareholders' equity | $17.96M | $48.43M | $107.88M | $174.13M | $242.54M | $305.49M | $364.41M | $413.64M |
| Net debt | -$48.10M | -$60.45M | -$29.33M | -$139.39M | -$85.61M | -$72.33M | -$41.70M | -$214.94M |
| Shares outstanding | 91.87M | 88.95M | 88.76M | 87.86M | 87.02M | 86.80M | 80.78M | 78.23M |
| Cash flow statement | ||||||||
| Operating cash flow | -$54.44M | -$62.55M | -$85.85M | $117.27M | -$80.63M | -$28.78M | -$71.93M | $269.13M |
| Capital expenditure | $445,000 | $656,000 | $128,000 | $2.32M | $2.57M | $1.46M | $292,000 | $372,000 |
| Free cash flow | -$54.89M | -$63.20M | -$85.98M | $114.95M | -$83.19M | -$30.23M | -$72.22M | $268.76M |
| Investing cash flow | $9.60M | $92.21M | -$24.23M | -$64.60M | $93.97M | $58.94M | -$101.41M | -$94.95M |
| Financing cash flow | $32.54M | $1.50M | $69,000 | $1.14M | $0 | $515,000 | $143,000 | $806,000 |
| Depreciation & amortization | $329,000 | $369,000 | $355,000 | $403,000 | $164,000 | $224,000 | $241,000 | $204,000 |
| Stock-based compensation | $8.17M | $8.21M | $8.42M | $11.35M | $10.96M | $6.95M | $7.84M | $8.63M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.